mAbxience continues to expand production capacity with disposable ABEC bioreactor technology

BETHLEHEM, Pennsylvania .– (BUSINESS CHP) – ABEC, a global provider of engineering solutions and services for biotechnology production, today announced that mAbxience will equip its state-of-the-art cGMP facility in Leon, Spain with an additional ABEC 4000L CSR bioreactor. Following the successful delivery of the first 4000L CSR bioreactor in 2021, mAbxience has once again chosen ABEC’s innovative disposable technology to increase its CDMO business and capacity.

In April 2022 and after being approved in Europe, Canada and Japan, among others, the US Food and Drug Administration (FDA) approved a Biological Licensing Application (BLA) for bevacizumab-mali, which was developed by mAbxience and represents the third bio-like approved in the United States Combining innovation with cutting-edge research and development technology, mAbxience is committed to improving patients’ access to vital treatments. With the additional 4000 L CSR bioreactor, mAbxience will achieve even greater cell culture productivity and faster increase in process transfer.

“The continued growth of mAbxience in the biosimilar market speaks volumes about the value of our strategic partnerships, such as with ABECsaid Emmanuel Lepin, CEO of mAbxience. As we look to the future of healthcare, we are excited to be at the forefront of sustainable practices that will improve access to critical medicines.

“ABEC continues to lead the industry in bringing scale and productivity to disposable manufacturing,” said Scott Pickering, chairman and CEO of ABEC. “We are proud to continue to support the growth of mAbxience with our innovative CSR technology.”

About ABEC

Since 1974, ABEC has been a world leader in providing engineering technology solutions and manufacturing services in the biotechnology industry. Most of the world’s pharmaceutical and biotechnology companies are customers of ABEC; with many of today’s leading therapies manufactured from processes and equipment designed, manufactured, installed and serviced by ABEC. The unique value of ABEC is based on many years of experience, full internal capabilities, personalized, flexible approach and long-term reliability. Whether you are adding capacity or upgrading existing facilities, turnkey solutions and ABEC support services reduce overall costs and time to market while ensuring maximum productivity. To learn more about ABEC, visit, email info @ ab m and follow us on LinkedIn.

About mAbxience

MAbxience is a fully integrated global biopharmaceutical company specializing in the development, production and commercialization of monoclonal antibodies and CDMO services, and is part of the Insud Pharma pharmaceutical group. Founded in 2010, mAbxience operates three state-of-the-art facilities located in Spain and Argentina. mAbxience is working on several biopharmaceutical products covering different therapeutic areas. In 2014, mAbxience launched its first biosimilar product, Rituximab (Product Code: RTXM83-MB01), which is now approved and marketed in a number of markets around the world. Its second product, Bevacizumab (Product code: BEVZ92-MB02), was first developed and launched in Latin America in 2016. mAbxience is committed to the quality, safety and efficacy of its drugs. The mAbxience team is passionate about patient care and expanding access to its biopharmaceuticals around the world. The company’s mission is to improve patients’ access to quality treatments for conditions that require expensive drugs and contribute positively to the sustainability of health systems. Insud Pharma Group was founded by Dr. Hugo Sigman and Dr. Sylvia Gold and has over 40 years of experience in the pharmaceutical sector and employs over 6,000 professionals worldwide.

Leave a Comment